Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia.

Aydinok Y, Piga A, Origa R, Mufti N, Erickson A, North A, Waldhaus K, Ernst C, Lin JS, Huang N, Benjamin RJ, Corash L.

Br J Haematol. 2019 Aug;186(4):625-636. doi: 10.1111/bjh.15963. Epub 2019 May 30.

2.

Pregnancy in Thalassemia.

Origa R, Comitini F.

Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019019. doi: 10.4084/MJHID.2019.019. eCollection 2019. Review.

3.

Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.

Marktel S, Scaramuzza S, Cicalese MP, Giglio F, Galimberti S, Lidonnici MR, Calbi V, Assanelli A, Bernardo ME, Rossi C, Calabria A, Milani R, Gattillo S, Benedicenti F, Spinozzi G, Aprile A, Bergami A, Casiraghi M, Consiglieri G, Masera N, D'Angelo E, Mirra N, Origa R, Tartaglione I, Perrotta S, Winter R, Coppola M, Viarengo G, Santoleri L, Graziadei G, Gabaldo M, Valsecchi MG, Montini E, Naldini L, Cappellini MD, Ciceri F, Aiuti A, Ferrari G.

Nat Med. 2019 Feb;25(2):234-241. doi: 10.1038/s41591-018-0301-6. Epub 2019 Jan 21.

PMID:
30664781
4.

Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.

Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

Am J Hematol. 2019 Apr;94(4):E96-E99. doi: 10.1002/ajh.25408. Epub 2019 Jan 31. No abstract available.

5.

Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major.

Ponti ML, Comitini F, Murgia D, Ganga R, Canu R, Dessì C, Foschini ML, Leoni G, Morittu M, Perra M, Pilia MP, Casini MR, Zappu A, Origa R.

Dig Liver Dis. 2019 Apr;51(4):561-567. doi: 10.1016/j.dld.2018.12.016. Epub 2019 Jan 3.

PMID:
30658940
6.

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.

Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, Goh AS, Huang V, Zia A, Herranz RM, Porter JB.

Health Qual Life Outcomes. 2018 Nov 19;16(1):216. doi: 10.1186/s12955-018-1041-5.

7.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.

Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galactéros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O.

Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.

8.

Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited.

Derchi G, Dessì C, Bina P, Cappellini MD, Piga A, Perrotta S, Tartaglione I, Giuditta M, Longo F, Origa R, Quarta A, Pinto V, Forni GL; Webthal®.

Intern Emerg Med. 2019 Apr;14(3):365-370. doi: 10.1007/s11739-018-1890-2. Epub 2018 Jun 12.

PMID:
29948832
9.

Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study.

Floris F, Comitini F, Leoni G, Moi P, Morittu M, Orecchia V, Perra M, Pilia MP, Zappu A, Casini MR, Origa R.

Qual Life Res. 2018 Oct;27(10):2533-2539. doi: 10.1007/s11136-018-1911-7. Epub 2018 Jun 19.

PMID:
29922915
10.

Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias.

Origa R, Piga A, Tartaglione I, Della Corte G, Forni GL, Bruederle A, Castiglioni C, Han J.

Am J Hematol. 2018 Jul;93(7):E172-E175. doi: 10.1002/ajh.25122. Epub 2018 May 15. No abstract available.

11.

Beta-Thalassemia.

Origa R.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.
2000 Sep 28 [updated 2018 Jan 25].

12.

Hematological phenotypes in children according to the α-globin genotypes.

Origa R, Barella S, Paglietti ME, Anni F, Danjou F, Denotti AR, Desogus MF, Loi D, Orecchia V, Sollaino MC, Moi P.

Blood Cells Mol Dis. 2018 Mar;69:102-106. doi: 10.1016/j.bcmd.2017.10.003. Epub 2017 Nov 3.

PMID:
29162392
13.

Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.

Origa R, Ponti ML, Filosa A, Galeota Lanza A, Piga A, Saracco GM, Pinto V, Picciotto A, Rigano P, Madonia S, Rosso R, D'Ascola D, Cappellini MD, D'Ambrosio R, Tartaglione I, De Franceschi L, Gianesin B, Di Marco V, Forni GL; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE).

Am J Hematol. 2017 Dec;92(12):1349-1355. doi: 10.1002/ajh.24911. Epub 2017 Oct 19.

14.

Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment.

Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, Caria R, Pilia MP, Origa R, Moi P, La Nasa G.

Am J Hematol. 2017 Dec;92(12):1303-1310. doi: 10.1002/ajh.24898. Epub 2017 Sep 25.

15.

Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia.

Origa R, Tatti F, Zappu A, Leoni GB, Dessì C, Moi P, Morittu M, Orecchia V, Denotti AR, Pilia MP, Anni F, Perra M, Casini MR, Barella S.

Am J Hematol. 2017 Nov;92(11):E627-E628. doi: 10.1002/ajh.24869. Epub 2017 Sep 25. No abstract available.

16.

Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation.

Satta S, Paglietti ME, Sollaino MC, Barella S, Moi P, Desogus MF, Demartis FR, Manunza L, Origa R.

Blood Cells Mol Dis. 2017 May;64:30-32. doi: 10.1016/j.bcmd.2017.03.007. Epub 2017 Mar 18.

PMID:
28342932
17.

Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015.

Origa R, Anni F, Mereu L, Follesa I, Campus S, Dessì C, Foschini ML, Leoni G, Moi P, Morittu M, Orecchia V, Perra M, Zappu A, Podda RA.

Ann Hematol. 2017 Jun;96(6):1041-1042. doi: 10.1007/s00277-017-2963-4. Epub 2017 Mar 9. No abstract available.

PMID:
28280993
18.

New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.

Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB.

Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18.

19.

EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations.

Schotten N, Laarakkers CM, Roelofs RW, Origa R, van Kraaij MG, Swinkels DW.

Am J Hematol. 2017 Mar;92(3):E29-E31. doi: 10.1002/ajh.24636. No abstract available.

20.

Alpha-Thalassemia.

Origa R, Moi P.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.
2005 Nov 1 [updated 2016 Dec 29].

21.

β-Thalassemia.

Origa R.

Genet Med. 2017 Jun;19(6):609-619. doi: 10.1038/gim.2016.173. Epub 2016 Nov 3. Review.

PMID:
27811859
22.

Current growth patterns in children and adolescents with thalassemia major.

Origa R, Danjou F, Orecchia V, Zappu A, Dessì C, Foschini ML, Leoni GB, Moi P, Morittu M, Demurtas A, Loche S.

Blood. 2016 Nov 24;128(21):2580-2582. Epub 2016 Oct 13. No abstract available.

PMID:
27737888
23.

Deferasirox and children: From clinical trials to the real world.

Origa R, Zappu A, Foschini ML, Leoni G, Morittu M, Moi P, Corpino M, Dessì C.

Am J Hematol. 2016 Jun;91(6):E304-5. doi: 10.1002/ajh.24353. Epub 2016 Apr 13. No abstract available.

24.

The Problem of Borderline Hemoglobin A2 Levels in the Screening for β-Thalassemia Carriers in Sardinia.

Paglietti ME, Satta S, Sollaino MC, Barella S, Ventrella A, Desogus MF, Demartis FR, Manunza L, Origa R.

Acta Haematol. 2016;135(4):193-9. doi: 10.1159/000442194. Epub 2016 Jan 22.

PMID:
26794457
25.

A complicated disease: what can be done to manage thalassemia major more effectively?

Origa R, Baldan A, Marsella M, Borgna-Pignatti C.

Expert Rev Hematol. 2015 Dec;8(6):851-62. doi: 10.1586/17474086.2015.1101339. Epub 2015 Oct 15. Review.

PMID:
26470003
26.

The V736A TMPRSS6 polymorphism influences liver iron concentration in nontransfusion-dependent thalassemias.

Cau M, Danjou F, Chessa R, Serrenti M, Addis M, Barella S, Origa R.

Am J Hematol. 2015 Dec;90(12):E225-6. doi: 10.1002/ajh.24197. Epub 2015 Nov 17. No abstract available.

27.

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW.

Haematologica. 2016 Jan;101(1):38-45. doi: 10.3324/haematol.2015.133983. Epub 2015 Sep 18.

28.

Thalassemia Major: Who Is Afraid of Serum Ferritin below 500 μg/l?

Pinna F, Carta R, Morittu M, Dessì C, Moi P, Leoni G, Foschini ML, Defraia E, Zappu A, Origa R.

Acta Haematol. 2015;134(3):183-4. doi: 10.1159/000371866. Epub 2015 May 27. No abstract available.

PMID:
26022742
29.

Thalassemia major between liver and heart: Where we are now.

Dessì C, Leoni G, Moi P, Danjou F, Follesa I, Foschini ML, Morittu M, Zappu A, Defraia E, Bina P, Cunico A, Civolani A, Podda RA, Origa R.

Blood Cells Mol Dis. 2015 Jun;55(1):82-8. doi: 10.1016/j.bcmd.2015.03.010. Epub 2015 Apr 6.

PMID:
25976473
30.

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.

Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, Kilinç Y, Perrotta S, Karakas Z, Viprakasit V, Habr D, Constantinovici N, Shen J, Porter JB; HYPERION Investigators.

Blood. 2015 Jun 18;125(25):3868-77. doi: 10.1182/blood-2014-07-586677. Epub 2015 May 1.

31.

IFNL3 polymorphisms and HCV infection in patients with beta thalassemia.

Origa R, Marceddu G, Danjou F, Perseu L, Satta S, Demartis FR, Piga A, Longo F, Lai ME, Vacquer S, Galanello R.

Ann Hepatol. 2015 May-Jun;14(3):389-95.

32.

Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.

Origa R, Cazzola M, Mereu E, Danjou F, Barella S, Giagu N, Galanello R, Swinkels DW.

Haematologica. 2015 May;100(5):e169-71. doi: 10.3324/haematol.2014.115733. Epub 2015 Jan 16. No abstract available.

33.

A genetic score for the prediction of beta-thalassemia severity.

Danjou F, Francavilla M, Anni F, Satta S, Demartis FR, Perseu L, Manca M, Sollaino MC, Manunza L, Mereu E, Marceddu G, Pissard S, Joly P, Thuret I, Origa R, Borg J, Forni GL, Piga A, Lai ME, Badens C, Moi P, Galanello R.

Haematologica. 2015 Apr;100(4):452-7. doi: 10.3324/haematol.2014.113886. Epub 2014 Dec 5.

34.

Investigating the alpha1(NcoI) mutation.

Desogus MF, Paglietti ME, Sollaino MC, Barella S, Origa R.

Acta Haematol. 2015;133(2):145-7. doi: 10.1159/000363440. Epub 2014 Sep 20. No abstract available.

PMID:
25247841
35.

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD.

Br J Haematol. 2015 Jan;168(2):284-90. doi: 10.1111/bjh.13119. Epub 2014 Sep 12.

PMID:
25212456
36.

Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.

Piga A, Longo F, Origa R, Roggero S, Pinna F, Zappu A, Castiglioni C, Cappellini MD.

Br J Haematol. 2014 Nov;167(3):423-6. doi: 10.1111/bjh.12987. Epub 2014 Jun 30. No abstract available.

PMID:
24976388
37.

Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.

Cossu G, Abbruzzese G, Matta G, Murgia D, Melis M, Ricchi V, Galanello R, Barella S, Origa R, Balocco M, Pelosin E, Marchese R, Ruffinengo U, Forni GL.

Parkinsonism Relat Disord. 2014 Jun;20(6):651-4. doi: 10.1016/j.parkreldis.2014.03.002. Epub 2014 Mar 12.

PMID:
24661465
38.

A decisional algorithm to start iron chelation in patients with beta thalassemia.

Danjou F, Cabantchik ZI, Origa R, Moi P, Marcias M, Barella S, Defraia E, Dessì C, Foschini ML, Giagu N, Leoni GB, Morittu M, Galanello R.

Haematologica. 2014 Mar;99(3):e38-40. doi: 10.3324/haematol.2013.098202. No abstract available.

39.

Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up.

Derchi G, Balocco M, Bina P, Caruso V, D'Ascola DG, Littera R, Origa R, Cappellini MD, Forni GL.

Haematologica. 2014 Feb;99(2):e17-8. doi: 10.3324/haematol.2013.095810. No abstract available.

40.

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD.

Eur J Haematol. 2014 Jun;92(6):521-6. doi: 10.1111/ejh.12270. Epub 2014 Mar 25.

41.

α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia.

Origa R, Sollaino MC, Borgna-Pignatti C, Piga A, Feliu Torres A, Masile V, Galanello R.

Acta Haematol. 2014;131(3):162-4. doi: 10.1159/000353410. Epub 2013 Nov 6. No abstract available.

PMID:
24217654
42.

Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.

Origa R, Danjou F, Cossa S, Matta G, Bina P, Dessì C, Defraia E, Foschini ML, Leoni G, Morittu M, Galanello R.

Br J Haematol. 2013 Nov;163(3):400-3. doi: 10.1111/bjh.12517. Epub 2013 Aug 16.

PMID:
24033185
43.

Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia.

Origa R, Paglietti ME, Sollaino MC, Desogus MF, Barella S, Loi D, Galanello R.

Blood Cells Mol Dis. 2014 Jan;52(1):46-9. doi: 10.1016/j.bcmd.2013.06.004. Epub 2013 Jul 27.

PMID:
23896219
44.

Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment.

Danjou F, Origa R, Anni F, Saba L, Cossa S, Podda G, Galanello R.

Blood Cells Mol Dis. 2013 Oct;51(3):142-5. doi: 10.1016/j.bcmd.2013.06.001. Epub 2013 Jun 28.

PMID:
23816436
45.

Natural history of hepatitis C in thalassemia major: a long-term prospective study.

Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Anni F, Corrias C, Farci P, Congiu G, Galanello R.

Eur J Haematol. 2013 Jun;90(6):501-7. doi: 10.1111/ejh.12086. Epub 2013 Mar 14.

PMID:
23414443
46.

Deferasirox: pharmacokinetics and clinical experience.

Galanello R, Campus S, Origa R.

Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):123-34. doi: 10.1517/17425255.2012.640674. Epub 2011 Dec 19. Review.

PMID:
22176640
47.

Pathophysiology of beta thalassaemia.

Origa R, Galanello R.

Pediatr Endocrinol Rev. 2011 Mar;8 Suppl 2:263-70. Review.

PMID:
21705976
48.

Beta-thalassemia.

Galanello R, Origa R.

Orphanet J Rare Dis. 2010 May 21;5:11. doi: 10.1186/1750-1172-5-11. Review.

49.

Pregnancy and beta-thalassemia: an Italian multicenter experience.

Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, Galanello R.

Haematologica. 2010 Mar;95(3):376-81. doi: 10.3324/haematol.2009.012393. Epub 2009 Nov 10.

50.

Cholelithiasis in thalassemia major.

Origa R, Galanello R, Perseu L, Tavazzi D, Domenica Cappellini M, Terenzani L, Forni GL, Quarta G, Boetti T, Piga A.

Eur J Haematol. 2009 Jan;82(1):22-5. doi: 10.1111/j.1600-0609.2008.01162.x. Epub 2008 Oct 31.

PMID:
19021734

Supplemental Content

Support Center